vs
CSW INDUSTRIALS, INC.（CSW）与PHIBRO ANIMAL HEALTH CORP（PAHC）财务数据对比。点击上方公司名可切换其他公司
PHIBRO ANIMAL HEALTH CORP的季度营收约是CSW INDUSTRIALS, INC.的1.6倍（$373.9M vs $233.0M），PHIBRO ANIMAL HEALTH CORP净利率更高（7.3% vs 4.4%，领先2.9%），PHIBRO ANIMAL HEALTH CORP同比增速更快（20.9% vs 20.3%），CSW INDUSTRIALS, INC.自由现金流更多（$22.7M vs $8.3M），过去两年PHIBRO ANIMAL HEALTH CORP的营收复合增速更高（19.2% vs 5.1%）
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
CSW vs PAHC — 直观对比
营收规模更大
PAHC
是对方的1.6倍
$233.0M
营收增速更快
PAHC
高出0.6%
20.3%
净利率更高
PAHC
高出2.9%
4.4%
自由现金流更多
CSW
多$14.5M
$8.3M
两年增速更快
PAHC
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $233.0M | $373.9M |
| 净利润 | $10.3M | $27.5M |
| 毛利率 | 39.7% | 35.5% |
| 营业利润率 | 7.4% | 13.5% |
| 净利率 | 4.4% | 7.3% |
| 营收同比 | 20.3% | 20.9% |
| 净利润同比 | -61.9% | 762.1% |
| 每股收益（稀释后） | $0.62 | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSWPAHC
| Q4 25 | $233.0M | $373.9M | ||
| Q3 25 | $277.0M | $363.9M | ||
| Q2 25 | $263.6M | $378.7M | ||
| Q1 25 | $230.5M | $347.8M | ||
| Q4 24 | $193.6M | $309.3M | ||
| Q3 24 | $227.9M | $260.4M | ||
| Q2 24 | $226.2M | $273.2M | ||
| Q1 24 | $210.9M | $263.2M |
净利润CSWPAHC
| Q4 25 | $10.3M | $27.5M | ||
| Q3 25 | $40.7M | $26.5M | ||
| Q2 25 | $40.9M | $17.2M | ||
| Q1 25 | $35.1M | $20.9M | ||
| Q4 24 | $26.9M | $3.2M | ||
| Q3 24 | $36.1M | $7.0M | ||
| Q2 24 | $38.6M | $752.0K | ||
| Q1 24 | $31.8M | $8.4M |
毛利率CSWPAHC
| Q4 25 | 39.7% | 35.5% | ||
| Q3 25 | 43.0% | 32.9% | ||
| Q2 25 | 43.8% | 29.0% | ||
| Q1 25 | 44.2% | 30.1% | ||
| Q4 24 | 41.4% | 32.9% | ||
| Q3 24 | 45.6% | 32.1% | ||
| Q2 24 | 47.5% | 31.9% | ||
| Q1 24 | 44.4% | 30.2% |
营业利润率CSWPAHC
| Q4 25 | 7.4% | 13.5% | ||
| Q3 25 | 20.5% | 14.1% | ||
| Q2 25 | 20.8% | 8.9% | ||
| Q1 25 | 19.5% | 9.6% | ||
| Q4 24 | 15.3% | 8.3% | ||
| Q3 24 | 22.6% | 6.8% | ||
| Q2 24 | 24.3% | 6.7% | ||
| Q1 24 | 21.0% | 7.6% |
净利率CSWPAHC
| Q4 25 | 4.4% | 7.3% | ||
| Q3 25 | 14.7% | 7.3% | ||
| Q2 25 | 15.5% | 4.5% | ||
| Q1 25 | 15.2% | 6.0% | ||
| Q4 24 | 13.9% | 1.0% | ||
| Q3 24 | 15.8% | 2.7% | ||
| Q2 24 | 17.1% | 0.3% | ||
| Q1 24 | 15.1% | 3.2% |
每股收益（稀释后）CSWPAHC
| Q4 25 | $0.62 | $0.67 | ||
| Q3 25 | $2.41 | $0.65 | ||
| Q2 25 | $2.43 | $0.43 | ||
| Q1 25 | $2.05 | $0.51 | ||
| Q4 24 | $1.60 | $0.08 | ||
| Q3 24 | $2.26 | $0.17 | ||
| Q2 24 | $2.47 | $0.02 | ||
| Q1 24 | $2.03 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $40.2M | $74.5M |
| 总债务越低越好 | — | $624.2M |
| 股东权益账面价值 | $1.1B | $332.4M |
| 总资产 | $2.3B | $1.4B |
| 负债/权益比越低杠杆越低 | — | 1.88× |
8季度趋势，按日历期对齐
现金及短期投资CSWPAHC
| Q4 25 | $40.2M | $74.5M | ||
| Q3 25 | $31.5M | $85.3M | ||
| Q2 25 | $38.0M | $77.0M | ||
| Q1 25 | $225.8M | $70.4M | ||
| Q4 24 | $213.8M | $67.1M | ||
| Q3 24 | $273.2M | $89.8M | ||
| Q2 24 | $18.9M | $114.6M | ||
| Q1 24 | $22.2M | $98.7M |
总债务CSWPAHC
| Q4 25 | — | $624.2M | ||
| Q3 25 | — | $628.0M | ||
| Q2 25 | — | $631.7M | ||
| Q1 25 | $800.1M | $635.4M | ||
| Q4 24 | — | $639.1M | ||
| Q3 24 | — | $295.2M | ||
| Q2 24 | — | $312.1M | ||
| Q1 24 | $166.0M | — |
股东权益CSWPAHC
| Q4 25 | $1.1B | $332.4M | ||
| Q3 25 | $1.1B | $311.7M | ||
| Q2 25 | $1.1B | $285.7M | ||
| Q1 25 | $1.1B | $266.0M | ||
| Q4 24 | $1.0B | $246.8M | ||
| Q3 24 | $1.0B | $258.5M | ||
| Q2 24 | $650.2M | $256.6M | ||
| Q1 24 | $615.7M | $270.1M |
总资产CSWPAHC
| Q4 25 | $2.3B | $1.4B | ||
| Q3 25 | $1.5B | $1.4B | ||
| Q2 25 | $1.5B | $1.4B | ||
| Q1 25 | $1.4B | $1.3B | ||
| Q4 24 | $1.4B | $1.3B | ||
| Q3 24 | $1.4B | $966.3M | ||
| Q2 24 | $1.1B | $982.2M | ||
| Q1 24 | $1.0B | $979.0M |
负债/权益比CSWPAHC
| Q4 25 | — | 1.88× | ||
| Q3 25 | — | 2.01× | ||
| Q2 25 | — | 2.21× | ||
| Q1 25 | 0.75× | 2.39× | ||
| Q4 24 | — | 2.59× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.22× | ||
| Q1 24 | 0.27× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.9M | $19.4M |
| 自由现金流经营现金流 - 资本支出 | $22.7M | $8.3M |
| 自由现金流率自由现金流/营收 | 9.8% | 2.2% |
| 资本支出强度资本支出/营收 | 2.6% | 3.0% |
| 现金转化率经营现金流/净利润 | 2.81× | 0.70× |
| 过去12个月自由现金流最近4个季度 | $162.0M | $47.3M |
8季度趋势，按日历期对齐
经营现金流CSWPAHC
| Q4 25 | $28.9M | $19.4M | ||
| Q3 25 | $61.8M | $9.3M | ||
| Q2 25 | $60.6M | $21.3M | ||
| Q1 25 | $27.3M | $43.2M | ||
| Q4 24 | $11.6M | $3.1M | ||
| Q3 24 | $66.8M | $12.6M | ||
| Q2 24 | $62.7M | $28.4M | ||
| Q1 24 | $22.4M | $11.4M |
自由现金流CSWPAHC
| Q4 25 | $22.7M | $8.3M | ||
| Q3 25 | $58.7M | $-4.5M | ||
| Q2 25 | $57.7M | $8.1M | ||
| Q1 25 | $22.8M | $35.4M | ||
| Q4 24 | $8.5M | $-4.7M | ||
| Q3 24 | $61.3M | $3.0M | ||
| Q2 24 | $59.6M | $15.4M | ||
| Q1 24 | $17.5M | $1.7M |
自由现金流率CSWPAHC
| Q4 25 | 9.8% | 2.2% | ||
| Q3 25 | 21.2% | -1.2% | ||
| Q2 25 | 21.9% | 2.1% | ||
| Q1 25 | 9.9% | 10.2% | ||
| Q4 24 | 4.4% | -1.5% | ||
| Q3 24 | 26.9% | 1.2% | ||
| Q2 24 | 26.3% | 5.6% | ||
| Q1 24 | 8.3% | 0.6% |
资本支出强度CSWPAHC
| Q4 25 | 2.6% | 3.0% | ||
| Q3 25 | 1.1% | 3.8% | ||
| Q2 25 | 1.1% | 3.5% | ||
| Q1 25 | 2.0% | 2.2% | ||
| Q4 24 | 1.6% | 2.5% | ||
| Q3 24 | 2.4% | 3.7% | ||
| Q2 24 | 1.4% | 4.8% | ||
| Q1 24 | 2.3% | 3.7% |
现金转化率CSWPAHC
| Q4 25 | 2.81× | 0.70× | ||
| Q3 25 | 1.52× | 0.35× | ||
| Q2 25 | 1.48× | 1.24× | ||
| Q1 25 | 0.78× | 2.07× | ||
| Q4 24 | 0.43× | 0.97× | ||
| Q3 24 | 1.85× | 1.81× | ||
| Q2 24 | 1.62× | 37.80× | ||
| Q1 24 | 0.71× | 1.36× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
